At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study
In Brief
A Phase 1 clinical trial evaluating ipilimumab, gemcitabine hydrochloride, and 1 other intervention for Duct Cell Adenocarcinoma of the Pancreas and 3 related conditions. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This phase I trial studies the side effects and best dose of ipilimumab when given together with gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to kill tumor cells or stop them from growing. Giving monoclonal antibody therapy together with chemotherapy may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Correlative studies